Amneal Initiates Phase 3 Study for IPX203, an Investigational Extended-Release Formulation of Carbidopa-Levodopa (CD-LD) in Advanced Parkinson's Disease Patients

BRIDGEWATER, N.J., May 7, 2018 -- (Healthcare Sales & Marketing Network) -- Amneal (NYSE: AMRX), a specialty pharmaceutical company, today announced it has initiated a Phase 3 trial for IPX203. The IPX203 Phase 3 protocol has been agreed upon with the Foo... Biopharmaceutical, Neurology Amneal Pharmaceuticals, Parkinson's Disease, carbidopa, levodopa
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news